| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23963 | QL-47 | A potent, selective, and irreversible BTK inhibitor with IC50 of 7 nM. |
|
| DC21545 | PXS-4681A | A potent, selective, and irreversible inhibitor of SSAO/VAP-1 (AOC3) with Ki of 37 nM, IC50 of <10 nM. |
|
| DC21254 | LY-517717 | A potent, selective, and orally bioavailable factor Xa (FXa) inhibitor for prevention and treatment of thromboembolic diseases.. |
|
| DC21487 | PF-05190457 Featured | A potent, selective, and orally bioavailable ghrelin receptor (GHSR) inverse agonist with binding pKi of 8.36. |
|
| DC23541 | IRAK4-IN-16 | A potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associate kinase-4 (IRAK4) with IC50 of 2.8 nM, 217- and 892-fold selectivity over IRAK-1 and TAK1, respectively. |
|
| DC23949 | CX-6258 hydrochloride hydrate | A potent, selective, and orally efficacious pan-Pim inhibitor with IC50 of 5/25/16 nM for Pim1/2/3, respectively. |
|
| DC23036 | BI-69A11 | A potent, selective, ATP competitive AKT inhibitor with IC50 of 2.3 uM for Akt1. |
|
| DC22651 | PF-4950834 | A potent, selective, ATP-competitive and orally acitve Rho kinase inhibitor with IC50 of 33.1 and 8.5 nM for ROCK1 and ROCK2, respectively. |
|
| DC23867 | PF-00337210 | A potent, selective, ATP-competitive and orally bioavailable inhibitor of VEGFR-2 with Ki of 0.7 and 8.8 nM for unactivated and fully phosphorylated VEGFR-2, respectively. |
|
| DC23930 | Bay 65-1942 | A potent, selective, ATP-competitive inhibitor of IKKβ kinase with Ki of 2 nM. |
|
| DC22500 | Bay 65-1942 hydrochloride | A potent, selective, ATP-competitive inhibitor of IKKβ kinase with Ki of 2 nM. |
|
| DC23070 | MAP4K4-IN-11e | A potent, selective, ATP-competitive inhibitor of MAP4K4 with IC50 of 1.9 uM, without effect on other stress pathway related kinases. |
|
| DC23964 | BMS-509744 | A potent, selective, ATP-competitive ITK inhibitor with IC50 of 19 nM. |
|
| DC22551 | DFMTI | A potent, selective, brain penetrant and orally active mGluR1 antagonist with 4.3 nM and 3.6 nM for huam and rat mGluR1, respectively. |
|
| DC22895 | VU0477573 | A potent, selective, brain penetrant partial negative allosteric modulator of mGlu5 receptor with Ki of 14 nM, Ca assay IC50 of 32 nM. |
|
| DC22964 | PQ-10 Featured | A potent, selective, brain penetrant PDE10A inhibitor with Ki of 4 nM. |
|
| DC23695 | PF-05085727 | A potent, selective, brain penetrant phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 2 nM, >4,000-fold selectivity over PDE1 and PDE3-11. |
|
| DC22920 | AMN 082 dihydrochloride | A potent, selective, brain penetrant, orally acitve mGluR7 allosteric agonist that inhibits forskolin-stimulated cAMP accumulation in mGluR7b CHO cells with EC50 of 64±32 nM. |
|
| DC23640 | ASP2535 | A potent, selective, brain permeable, orally available glycine transporter-1 (GlyT1) inhibitor with IC50 of 92 nM (rat GlyT1), 50-fold selectivity over GlyT2. |
|
| DC20549 | SHP2 inhibitor 11a-1 | A potent, selective, cell active SHP2 inhibitor with IC50 of 200 nM, displays >5-fold selectivity against 20 other mammalian PTPs. |
|
| DC22877 | CPI703 | A potent, selective, cell-active CBP/EP300 bromodomain inhibitor with IC50 of 0.47 uM for CBP. |
|
| DC25052 | Src I338G-IN-3g | A potent, selective, cell-permeable I338G v-Src inhibitor with IC50 of 430 nM, shows no inhibition of wild-type v-Src at 300 uM. |
|
| DC21474 | PF-04781340 | A potent, selective, CNS penetrant 5-HT2C receptor agonist with Ki of 3 nM and EC50 of 9 nM, without significant P-gp efflux liability. |
|
| DC22708 | VU 0255035 | A potent, selective, CNS penetrant and competitive orthosteric antagonist of M1 mAChR with IC50 of 132 nM, >75-fold selectivity over M2-M5. |
|
| DC22667 | mGlu5 PAM 4k | A potent, selective, CNS penetrant and orally bioavailable mGlu5 positive allosteric modulator that potentiates human mGlu5 with EC50 of 130 nM. |
|
| DC22684 | JNJ-46778212 Featured | A potent, selective, CNS penetrant and orally bioavailable mGlu5 positive allosteric modulator that potentiates human mGlu5 with EC50 of 260 nM. |
|
| DC22730 | JNJ-42253432 | A potent, selective, CNS-penetrant P2X7 antagonist with pKi of 9.1 and 7.9 for rat and huamn P2X7 channel, respectively. |
|
| DC22903 | SW-106 Featured | SW106 is a potent, selective, competitive PTH/PTH-related peptide receptor (PPR) antagonist with IC50 of 0.99 uM. |
|
| DC23069 | KRAS G12C inhibitor 1 | A potent, selective, covalent KRAS G12C inhibitor that selectively inhibit KRAS G12C-dependent signaling and cancer cell growth at sub-micromolar concentrations.. |
|
| DC21442 | ONO 2050297 | A potent, selective, dual CysLT1 and CysLT2 antagonist with IC50 of 17 and 0.87 nM, respectively.. |
|
